UMMS Affiliation

Department of Medicine; Division of Infectious Diseases and Immunology; Department of Pharmacology and Molecular Toxicology



Document Type



Anti-Bacterial Agents; DNA Polymerase III; Enterococcus; Enzyme Inhibitors; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Staphylococcus aureus; Uracil


Immunology and Infectious Disease | Pharmacology | Toxicology


The 6-anilinouracils are novel dGTP analogs that selectively inhibit the replication-specific DNA polymerase III of gram-positive eubacteria. Two specific derivatives, IMAU (6-[3'-iodo-4'-methylanilino]uracil) and EMAU (6-[3'-ethyl-4'-methylanilino]uracil), were substituted with either a hydroxybutyl (HB) or a methoxybutyl (MB) group at their N3 positions to produce four agents: HB-EMAU, MB-EMAU, HB-IMAU, and MB-IMAU. These four new agents inhibited Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Time-kill assays and broth dilution testing confirmed bactericidal activity. These anilinouracil derivatives represent a novel class of antimicrobials with promising activities against gram-positive bacteria that are resistant to currently available agents, validating replication-specific DNA polymerase III as a new target for antimicrobial development.

Rights and Permissions

Citation: Antimicrob Agents Chemother. 2000 Aug;44(8):2217-21.

Related Resources

Link to article in PubMed

PubMed ID




To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.